Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals Inc. was formed in 2008 to commercialize innovative drug discovery technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon is pursuing clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and improved safety profiles. Our lead drug candidate, ACY-1215, is an oral small molecule inhibitor of HDAC6 currently in Phase Ib clinical trials in multiple myeloma in North America. The company has several additional pipeline programs for the development of selective HDAC inhibitors for neurodegenerative and inflammatory diseases, sickle disease and beta-thalassemia, and parasitic diseases which are approaching clinical development. Acetylon has raised $55M to date from private investors, The Leukemia and Lymphoma Society, and Celgene. Acetylon is located in a newly built facility in Boston's Seaport District / Innovation Zone.Back to list